Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2025 Earnings Call Transcript
Operator: Hello, and thank you for standing by. Welcome to Allogene Therapeutics Third Quarter 2025 Conference Call.
Allogene Therapeutics Inc. (ALLO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Levin Capital Strategies John A. Levin | 13,125 | $17,981 | -75% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.90 | 1,724,137 | $4,999,997.30 | 1,724,137 | 2024-05-16 | Filing | |
| $3.60 | 190 | $683.05 | 819,590 | 2024-01-30 | Filing | |
| $12.60 | 15,000 | $189,000.00 | 258,885 | 2022-01-12 | Filing | |
| $12.60 | 155,039 | $1,953,491.40 | 195,039 | 2022-01-12 | Filing | |
| $47.00 | 106,382 | $4,999,954.00 | 1,798,163 | 2020-06-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.56 | 26,269 | $40,979.64 | 616,866 | 2026-01-21 | Filing | |
| $1.22 | 786 | $958.92 | 217,721 | 2025-11-17 | Filing | |
| $1.26 | 36,744 | $46,168.84 | 1,276,796 | 2025-10-21 | Filing | |
| $1.42 | 36,885 | $52,376.70 | 107,431 | 2025-06-10 | Filing | |
| $1.41 | 9,601 | $13,537.41 | 130,663 | 2025-04-21 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,251,609 | $12,674,704 | 0% | |
| 2. | 2,086,332 | $2,858,275 | 0% | |
| 3. | 1,389,593 | $1,903,743 | 0% | |
| 4. | 86,215 | $118,115 | 0.06% | |
| 5. | 55,583 | $78,372 | 0% |
News See All
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q2 2025 Earnings Call Transcript
Operator: Hello, and thank you for standing by, and welcome to Allogene Therapeutics Second Quarter 2025 Conference Call.
Allogene Therapeutics Presents Promising Phase 1 Data for ALLO-316 in Renal Cell Carcinoma
On June 1, Allogene Therapeutics Inc.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2025 Earnings Call Transcript
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2025 Earnings Call Transcript May 13, 2025Allogene Therapeutics, Inc. reports earnings inline with expectations.
10 Low Risk High Reward Stocks Set to Triple by 2030
The market is getting tough these days with increasing interest rates, tense world politics, and inconsistent economic conditions, and investors are constantly looking for opportunities.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2024 Earnings Call Transcript
Operator: Hello. Thank you for standing by and welcome to Allogene Therapeutics fourth quarter and full year 2024 conference call.
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2024 Earnings Call Transcript
Operator: Hello, and thank you for standing by. Welcome to Allogene Therapeutics' Third Quarter 2024 Conference Call. After the speakers' presentation, there will be a question-and-answer session.
7 Best Rising Penny Stocks To Invest In Now
In an episode of Market Storylines on the Inside the Icehouse Podcast feed by Intercontinental Exchange, Jay Woods, Chief Global Strategist at Freedom Capital Markets, discussed Fed rate cuts and the ...
10 Worst Cancer Stocks To Buy Now According to Short Sellers
Cancer is the second leading cause of death globally, just behind cardiovascular disease, making oncology one of the largest sectors in the life sciences.
Top 10 Small-Cap Stocks with Highest Upside Potential
Most giant companies start as small-cap, but by continuously developing and growing their earnings, their share price increases making them large or mega-cap companies, and along the way smart investors...
Hedge Fund Resource Center Billionaire Hedge Funds
